Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Astrazeneca : H1 2021 results

07/30/2021 | 11:43am EDT

Astrazeneca - H1 2021 results

Pascal Soriot, Chief Executive Officer, commenting on the results said: 'AstraZeneca has delivered another period of strong growth thanks to robust performances across all regions and disease areas, particularly Oncology, New CVRM and Fasenra in Respiratory.

As a result, we have delivered further earnings progression, supported ongoing launches, and continued our investment in R&D.

We continue to advance our portfolio of life-changing medicines with further significant progress across disease areas. In Oncology, we recently presented Lynparza's OlympiA Phase III trial at the plenary session of the 2021 American Society of Clinical Oncology Annual Meeting, and we also shared the final results from Calquence's head-to-head trial with ibrutinib. In BioPharmaceuticals, the US approved Farxiga for chronic kidney disease and granted tezepelumab Priority Review to treat patients with asthma. Alexion will enable us to enhance our pipeline, extending the Company's presence in rare diseases and immunology with its complement biology.

Following the successful acquisition of Alexion, we are today updating our full-year 2021 guidance; our long-term goals to accelerate scientific discovery, invest for sustainable growth and deliver more benefits for patients remains unchanged.'

Contact:

Tel: +44 (0)20 3749 5000

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about ASTRAZENECA PLC
10:06aShangula Rages Against West's Vaccine Nationalism
AQ
08:35aASTRAZENECA : India calls new UK COVID-19 vaccine rules 'discriminatory'
AQ
07:02aASTRAZENECA : Investment will transform development and commercialisation of new medicines..
PU
06:23aEUROPEAN MIDDAY BRIEFING : Stocks Rebound But -2-
DJ
05:42aASTRAZENECA : to Invest $360 Million in New Irish Manufacturing Facility
MT
02:51aCapital.com Announces Top Hire to Drive Growth in Asia
DJ
02:45aAstraZeneca to invest $360 million in Irish drug manufacturing site
RE
02:25aASTRAZENECA : Plans New $360 Million Irish Manufacturing Site
MT
02:12aASTRAZENECA : to invest $360m in advanced manufacturing facility in Ireland
PU
12:23aAstraZeneca to Build $360 Million Manufacturing Plant in Dublin
DJ
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 401 M - -
Net income 2021 5 006 M - -
Net Debt 2021 24 250 M - -
P/E ratio 2021 32,7x
Yield 2021 2,41%
Capitalization 181 B 181 B -
EV / Sales 2021 5,80x
EV / Sales 2022 4,70x
Nbr of Employees 76 100
Free-Float 96,3%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 116,93 $
Average target price 135,96 $
Spread / Average Target 16,3%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC16.86%181 312
JOHNSON & JOHNSON4.09%431 227
ROCHE HOLDING AG10.52%321 941
PFIZER, INC.19.23%247 816
NOVO NORDISK A/S48.69%229 255
ELI LILLY AND COMPANY37.20%210 000